Small-molecule direct thrombin inhibitors: 1997 - 2000

Expert Opinion on Therapeutic Patents

Volumn 11, Issue 5, 2001, Pages 721-738

  Coburn, C A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Anticoagulant; Antithrombotic; Peptide mimetic; Small molecule; Thrombin; Thrombin inhibitor

Indexed keywords

ACETYL DEXTRO PHENYLALANYLPROLYLBOROARGININE; AMIDINOINDOLE DERIVATIVE; ANTITHROMBIN III; ARGATROBAN; AT 1362; BENZIMIDAZOLE DERIVATIVE; BENZOTHIOPHENE DERIVATIVE; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8A; BLOOD CLOTTING FACTOR 9A; CVS 1123; EFEGATRAN; FIBRIN; FIBRINOGEN; GR 133686; MELAGATRAN; NATURAL PRODUCT; PEPTIDE DERIVATIVE; PROTEIN C; PROTHROMBIN A; RWJ 50353; S 18326; SMALL MOLECULE DIRECT THROMBIN INHIBITOR; THROMBIN; THROMBIN INHIBITOR; THROMBOPLASTIN; TRYPSIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; XU 817;

ANIMAL EXPERIMENT; ANIMAL MODEL; BLEEDING; BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVALENT BOND; DRUG BINDING SITE; DRUG CLASSIFICATION; DRUG DESIGN; DRUG HALF LIFE; DRUG RESEARCH; DRUG STABILITY; DRUG TARGETING; ENZYME ACTIVE SITE; HUMAN; HYDROGEN BOND; LITERATURE; NONHUMAN; PATENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RAT; REVIEW;

EID: 0035021780     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.11.5.721     Document Type: Review

References (51)

1. st century
2. Future antithrombotic therapy
3. Small-molecule direct thrombin inhibitors
4. Direct thrombin inhibitors: Current status and future prospects
5. Strategies and progress towards the ideal orally active thrombin inhibitor
6. Small, noncovalent serine protease inhibitors
7. The development of novel noncovalent thrombin inhibitors
8. Direct thrombin inhibitors
9. Direct thrombin inhibitors
10. Anticoagulants: Thrombin and Factor Xa inhibitors
11. New advances in the discovery of thrombin and Factor Xa inhibitors
12. Molecules in focus: Thrombin
13. Multifunctional roles of thrombin
14. Thrombin structure and function: Why thrombin is the primary target for antithrombotics
15. Direct thrombin inhibitors in cardiovascular medicine
16. Heparin
17. Drug interactions with warfarin
18. Successors to heparin: New antithrombotic agents
19. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors
20. Crystal structures of thrombin and thrombin complexes as a framework for antithrombotic drug design
21. The ideal anti-thrombotic drug
22. 1,2-Disubstituted cyclohexane derived tripeptide aldehydes as novel selective thrombin inhibitors
23. Potent thrombin inhibitors that probe the S1′ subsite: Tripeptide transition state analogs based on a heterocycle-activated carbonyl group
24. Antithrombotic properties of RWJ-50353, a potent and novel thrombin inhibitor
25. Secondary structure peptide mimetics: Design, synthesis and evaluation of β-strand mimetic thrombin inhibitors
26. Potent and selective bicyclic lactam inhibitors of thrombin: Part 2: P1 modifications
27. The design of potent, selective, non-covalent, peptide thrombin inhibitors utilizing imidazole as a S1 binding element
28. L-376,062. A potent, selective, noncovalent thrombin inhibitor bearing a novel imidazole P1 ligand
29. Discovery and development of the novel potent orally active thrombin inhibitor N-(9-hydroxy-9-fluorenecarboxy) prolyl-trans-4-aminocyclohexylmethylamide (L-372,460): Coapplication of synthesis on solid support
30. Design of orally active non-peptidic inhibitors of human leukocyte elastase
31. L-374,087, an efficacious, orally bioavailable, pyridinone acetamide thrombin inhibitor
32. Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopyridinone or 3-aminopyrazinone acetamide peptidomimetic templates
33. Identification of oxidative degradates of the thrombin inhibitor, 3-(2 -phenethylamino)-6 -methyl-1-(2 -amino-6-methyl-5 -methylene -carboxamidom ethylpyridinyl)pyrazinone, using liquid chromatography/mass chromatography/tandem mass spectrometry
34. Bicyclic pyridones as potent, efficacious and orally biovailable thrombin inhibitors
35. Design, synthesis and structure activity relationship of a new class of bicyclic thrombin inhibitors
36. Discovery of LB30057, a benzamidrazone-based selective oral thrombin inhibitor
37. Design, synthesis and testing of amino-bicycloaryl based orally bioavailable thrombin inhibitors
38. Studies towards the identification of potent, selective and bioavailable thrombin inhibitors
39. Derivatives of 4-amino-pyridine as selective thrombin inhibitors
40. In vitro evaluation and crystallographic analysis of a new class of selective, non-amide-based thrombin inhibitors
41. Structure-activity and crystallographic analysis of a class of non-amide-based thrombin inhibitor
42. Structural analysis of thrombin complexed with potent inhibitors incorporating a phenyl group as a peptide mimetic and aminopyridines as guanidine substitutes
43. Identification and SAR for a selective, nonpeptidyl thrombin inhibitor
44. Amidino-substituted aromatic heterocycles as probes of the specificity pocket of trypsin-like proteases
45. Design and synthesis of potent and selective 5,6-fused heterocyclic thrombin inhibitors
46. In vitro and in vivo studies of AT-1362, a newly synthesized and orally active inhibitor of thrombin
47. Dibasic benzo[b]thiophene derivatives as a novel class of active site-directed thrombin inhibitors. 1. Determination of the serine protease selectivity, structure-activity relationships and binding orientation
48. Diamino benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors. 5. Potency, efficacy and pharmacokinetic properties of modified C-3 side chain derivatives
49. Novel natural product 5,5-trans-lactone inhibitors of human α-thrombin: Mechanism of action and structural studies
50. Synthesis of trans-fused[5,5]bicyclic lactones/lactams as templates for serine protease inhibition